ClinicalTrials.gg
Not yet recruitingNCT07512323Updated May 6, 2026

Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency

A Phase 2 interventional study of Nebido (Testosterone Undecanoate) in Frail Elderly Patients, Hypogonadal Males and Testosterone Replacement Therapy, sponsored by Rune Skovgaard Rasmussen. Not yet recruiting at 1 site in Denmark. Open to male participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Rune Skovgaard Rasmussen · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
70 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing testosterone undecanoate in Hypogonadism — 3 open to participants now, 3 under way, none of them phase 3. testosterone undecanoate · Hypogonadism.

Planned enrollment
11th of 26
96 · median 56
Started
2026
the only one that year
Phase 2
9 of 26
2 open now
Registered
26th of 26
by date
Lead sponsor
1 of 26
Rune Skovgaard Rasmussen

Among the 26 studies testing testosterone undecanoate in Hypogonadism, this one is the 11th largest by planned enrollment, is the only one that started in 2026, is one of 9 in phase 2, and was the 26th registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

3 of the 26 studies testing testosterone undecanoate in Hypogonadism are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About testosterone undecanoate

testosterone undecanoate: first FDA approval 2014 (AVEED), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 70 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing testosterone undecanoate in Hypogonadism, or all of them as a file.
02

Study summary

The purpose of this study is to increase the functional level of the elderly to thereby reduce fall risk, improve motor skills, and increase psychological well-being, as well as to assess whether the restoration of a normal testosterone level contributes to a faster recovery. The effect of testosterone is investigated as measured by physical and mental functional capacity, including cognition, in hypogonadal elderly men with a significant loss of function. The study is aimed at participants who are too weak to participate in the progressive strength training.

Read the detailed description

Please see the uploaded study protocol.

03

Conditions studied

  • Frail Elderly Patients
  • Hypogonadal Males
  • Testosterone Replacement Therapy
  • Falls (Accidents) in Old Age

Keywords

  • hypogonadism
  • frailty
  • falls
  • testosterone replacement therapy
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 70 or over.
  • Living at home in their own home or in sheltered housing.
  • Independent walking function, possibly with a walking aid.
  • Able to perform the chair-stand test a maximum of 8 times in 30 seconds or Timed Up and Go (TUG) of at least 30 seconds.
  • There must be at least 3 symptoms of frailty or objective findings.
  • Serum testosterone \< 10 nmol/L as an average of 2 independent measurements at the Center for Growth and Reproduction, Rigshospitalet.

Exclusion criteria

Exclusion Criteria:

  • Known or previous prostate cancer.
  • Abnormally elevated serum PSA (PSA = prostate-specific antigen) corresponding to PSA > 5 ng/ml or PSA > 0.15 ng/ml/cc (relative to prostate size in cubic centimeters (cc)).
  • Hemochromatosis.
  • Heart diseases in the form of: Peri-, myo-, or endocarditis, angina pectoris, severe heart failure ( class III and IV), severe hypertension (systolic BP > 180 or diastolic BP > 105 mmHg after possible antihypertensive treatment). - Resting dyspnea.
  • Liver (ASAT > 2 x upper normal limit) or renal insufficiency (serum creatinine > 200 micromol/l).
  • Severe intractable epilepsy or migraine.
  • Insulin treatment.
  • Previous or current bisphosphonate, fluoride, HRT, SERM, strontium, teriparatide, or more than 3 weeks of prednisolone treatment.
  • Joint disease with acute inflammation.
  • Active cancer disease, in chemo- or radiotherapy.
  • Bone metabolic disease except for age-related osteoporosis.
  • diseases, chronic systemic diseases (cirrhosis, AIDS, chronic renal failure).
  • Primary testosterone deficiency in the form of testicular dysgenesis, Klinefelter syndrome (47,XXY), 46,XX males, LH resistance, Y chromosome deletions, other sex chromosome abnormalities.
  • Significant abuse, mental illness, dementia, physical handicaps with inability to complete the intervention or tests, or to give .
  • for testosterone undecanoate are thus included in exclusion criteria, such as the presence of liver tumors, breast carcinoma, and prostate cancer, for which trial participants will be examined before the start of the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • No intervention
    Placebo

    Patients receiving placebo

  • Active comparator
    Intervention

    Patients receiving testosterone undecanoate

    Drug: Nebido (Testosterone Undecanoate)

Interventions

  • DrugTestosterone undecanoateStudies of Testosterone undecanoateTestosterone undecanoate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Testosterone supplementation is given intramuscularly with 1000 mg testosterone undecanoate, which has an effect for approx. 12 weeks, but which can be repeated more frequently between the 1st and 2nd administration. The injection is thus repeated in week 6. 3 injections per trial subject are expected, i.e., in weeks 1, 6, and 16. If the participants are motivated to continue so that long-term effects can be measured, the participants will be asked in week 12 whether they wish to continue to week 52. Upon acceptance of continuation to week 52, testosterone and placebo injections are offered according to original groups in weeks 26, 36, and 46, after which testing of primary and secondary endpoints is not only performed in week 20 but also in week 52.

    Also known as: Intervention, Experimental

06

What researchers measure

Primary outcomes

  1. Chair-stand test

    A measure of general strength in extremities. Number of times the participant can stand up and sit down from a chair in 30 seconds. A good correlation (r=0.78) has been found with leg press and acceptable test-retest reliability (ICC=0.86). It has recently been scientifically documented that the ability among elderly persons to perform this simple test correlates with the risk of serious fall accidents

    Time frame: At weeks 0, 4 and 20.

Secondary outcomes

  1. Measurement of fall frequency and severity

    Registered via a questionnaire for each trial subject and is also included in the monitoring of adverse events.

    Time frame: At weeks 0, 4 and 20.

  2. Balance ability

    Tested via the Tandem test, which contains three starting positions: 1) Standing with feet together, standing in semi-tandem stance, and standing in tandem stance.

    Time frame: At weeks 0, 4 and 20.

  3. Avlund's mobility scale

    Questions about experiencing fatigue and need for support in common activities of daily living. Avlund's mobility scale is correlated with isometric muscle strength, simple functional tests, increased risk of hospitalizations, and mortality. Good inter- and intra-reliability (kappa 0.72-1.00) has been shown. Scores range from 0 to 6, and higher scores indicate worse outcome.

    Time frame: At weeks 0, 4 and 20.

  4. Geriatric Depression Scale (GDS)

    Questionnaire about depression and psychological well-being. Scores range from 0 til 15. Score below 5 are normal, while scores of 5 or higher indicate varying degrees of depression, scoring 13-15 indicates severe depression.

    Time frame: At weeks 0, 4 and 20.

  5. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment is a cognitive screening instrument which provides an estimate of the level of intellectual functioning. Scores are from 0 to 30, where a score of 26 or higher is considered normal. Montreal Cognitive Assessment is moreover sensitive to mild cognitive problems as well as dementia. Studies have shown that Montreal Cognitive Assessment is more sensitive than Mini Mental State Examination to detecting mild cognitive changes and is as effective in identifying the incidence of Alzheimer's disease.

    Time frame: At weeks 0, 4 and 20.

  6. Mini Mental State Examination (MMSE)

    Cognitive screening test that provides an estimate of the intellectual functional level. This test is included as it is performed as standard at the Geriatric Outpatient Clinic. Combined, MMSE and MoCA provide a broader assessment of cognitive functional level. Scores range from 0 to 30, higher scores indicate better cognitive status. Scores from 26 to 30 are considered normal.

    Time frame: At weeks 0, 4 and 20.

  7. Quality of life EQ-5D

    Questionnaire about perceived quality of life. Scores range from 0 to 1 (first scale) and from 0 to 100 (second scale). Higher scores indicate better quality of life.

    Time frame: At weeks 0, 4 and 20.

  8. Clinical Frailty Scale (CFS)

    General assessment of health and functional level in the elderly. Scoring ranges from 1 to 9, and higher scores indicate more frailty.

    Time frame: At weeks 0, 4 and 20.

  9. Falls Efficacy Scale - International (FES-I, Fear of falling). Scores range from 16 to 64, and higher scores indicate increased anxiety of having a severe fall accident.

    Assessment of fall risk in the elderly.

    Time frame: At weeks 0, 4 and 20.

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — If there is interest, we will consider sharing data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Sep 2029, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 6, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2030
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07512323
Lead sponsor
Rune Skovgaard Rasmussen
Responsible party
Rune Skovgaard Rasmussen (MSc, PhD, associate professor of general pathology, University Hospital, Gentofte, Copenhagen) — Sponsor-investigator
First posted
Apr 6, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
May 6, 2026

Study contacts

Rune S. Rasmussen, MSc, PhD
Contact
rsr@sund.ku.dk
+4528757500
Karsten Overgaard, MD, Neurologist
Contact
Karsten.Overgaard@regionh.dk
26172611
Mette Midttun, MD, DMSc
principal investigator · Holbaek Sygehus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Testosterone undecanoate

Start the discussion